# Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence

> **NCT01848054** · PHASE3 · COMPLETED · sponsor: **Orexo AB** · enrollment: 313 (actual)

## Conditions studied

- Opioid-Related Disorders
- Opiate Dependence

## Interventions

- **DRUG:** Buprenorphine/naloxone sublingual tablets
- **DRUG:** Buprenorphine

## Key facts

- **NCT ID:** NCT01848054
- **Lead sponsor:** Orexo AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 313 (ACTUAL)
- **Last updated:** 2017-05-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01848054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01848054, "Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT01848054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*